乳腺导管原位癌的种族/民族肿瘤生物学与治疗差异
基于美国国家癌症数据库2012-2021年成人导管原位癌数据,比较不同种族/民族在肿瘤生物学特征和治疗上的差异。非西班牙裔黑人肿瘤更大、多中心病变更常见,非西班牙裔白人III级和ER阴性比例更高。非白人、无保险和医疗补助保险与不接受手术及治疗延迟相关。
要点
- 非西班牙裔黑人导管原位癌平均肿瘤更大(2.2 cm),多中心病变在非西班牙裔黑人和西班牙裔中更常见。
- 非白人种族/民族、无保险和医疗补助保险患者接受原发部位手术的可能性更低,且诊断至手术、手术至放疗时间更长。
- 西班牙裔患者保乳术后放疗比例较低(68.8%),ER阳性导管原位癌内分泌治疗以非西班牙裔黑人最高(61.9%)、亚洲患者最低(56.9%)。
核心结论
- 导管原位癌存在种族/民族肿瘤生物学和治疗差异,可能共同导致不同群体的预后差异。
研究设计与样本
- 回顾性队列研究,数据来自美国国家癌症数据库2012-2021年成人导管原位癌患者,采用卡方或Wilcoxon检验进行组间比较,多变量logistic回归评估治疗及治疗时间的预测因素。
主要发现
- 非西班牙裔黑人平均肿瘤大小2.2 cm(P ≤ .001),非西班牙裔黑人和西班牙裔多中心病变比例分别为14.7%和14.3%(P < .001)。
- 非西班牙裔白人III级和ER阴性比例分别为45.1%(P < .01)和14.2%(P < .04)。
- 多变量分析中非白人种族/民族接受原发部位手术的OR:非西班牙裔黑人1.80、西班牙裔1.23、亚洲/太平洋岛民1.45(均P ≤ .002)。
- 无保险和医疗补助保险接受原发部位手术的OR分别为2.76和1.39(均P < .002)。
- 亚洲患者接受乳房切除术OR 1.08(95%CI 1.02-1.15,P = .007),年轻年龄OR 0.64(P < .001),多中心病变HR 2.23(P < .001)。
临床怎么用
- 临床接诊导管原位癌时应关注种族/民族及保险类型相关的治疗差异,主动评估手术和辅助治疗的可及性。
- 对非白人、无保险或医疗补助保险患者,需警惕手术及放疗延迟风险,优化转诊和治疗衔接。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Racial differences in invasive breast cancer exist, but less is known about ductal carcinoma in situ. Our aim was to assess racial/ethnic differences in ductal carcinoma in situ tumor biology and treatment. METHODS: Adults with ductal carcinoma in situ were identified from the National Cancer Database, 2012-2021. Pairwise comparisons were evaluated among racial/ethnic groups with χ2 or Wilcoxon tests. Multivariable logistic regression models evaluated outcome predictors for treatment and time to treatment. RESULTS: Non-Hispanic Black patients had larger mean tumor size (2.2 cm, P ≤ .001). Non-Hispanic Black and Hispanic patients more frequently presented with multicentric disease (14.7% and 14.3%, P < .001). Non-Hispanic White patients had more grade III (45.1%, P < .01) and estrogen receptor-negative disease (14.2%, P < .04). On multivariable analysis, non-White race/ethnicity patients were less likely to undergo primary-site surgery (non-Hispanic Black odds ratio, 1.80; Hispanic odds ratio, 1.23; Asian/Pacific Islander odds ratio; 1.45, vs non-Hispanic White each P ≤ .002), as were uninsured and Medicaid-insured (uninsured odds ratio, 2.76; Medicaid odds ratio, 1.39; vs private insurance, both P < .002). Asian patients were more likely to undergo mastectomy (odds ratio, 1.08; 95% confidence interval, 1.02-1.15, P = .007), along with younger age (odds ratio, 0.64, P < .001), and multicentricity (hazard ratio, 2.23, P < .001). For breast conservation, radiation was less frequent among Hispanic patients (68.8%, P < .001). For estrogen receptor-positive ductal carcinoma in situ, non-Hispanic Black patients had the greatest receipt of endocrine therapy (61.9%%, P < .001) and Asian patients the lowest (56.9%, P < .001). On multivariable analysis, non-White race/ethnicity, uninsured, and Medicaid were associated with longer times from diagnosis to first surgery and from definitive surgery to radiation start. CONCLUSIONS: Racial/ethnic differences exist in ductal carcinoma in situ tumor biology and treatment, both of which may contribute to poorer outcomes in disparate groups.
引用
- Black DM, Day CN, Piltin MA, et al. Racial/ethnic differences in tumor biology and treatment outcomes in women with ductal carcinoma in situ. Surgery. 2024. PMID: 39603875. doi:10.1016/j.surg.2024.08.059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。